Filtered By:
Specialty: Drugs & Pharmacology
Cancer: Lung Cancer

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 140 results found since Jan 2013.

14,15 β‐dihydroxyklaineanone inhibits HepG2 cell proliferation and migration through p38MAPK pathway
Conclusions14,15 β‐dihydroxyklaineanone inhibited cell proliferation and migration through regulating p38 MAPK pathway in HCC cells.
Source: Journal of Pharmacy and Pharmacology - May 16, 2020 Category: Drugs & Pharmacology Authors: Xiao ‐Dong Pei, Song‐Qing He, Li‐Qun Shen, Jing‐Chen Wei, Xue‐Sheng Li, Yan‐Yan Wei, Yu‐Meng Zhang, Xin‐Yu Wang, Feng Lin, Zhi‐Long He, Li‐He Jiang Tags: Research Paper Source Type: research

Activation of notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus.
Abstract The mammalian target of rapamycin (mTOR) pathway converges diverse environmental cues to support the lung cancer growth and survival. However, the mTOR-targeted mono-therapy does not achieve expected therapeutic effect. Here, we revealed that fangchinoline (FCL), an active alkaloid that purified from the traditional Chinese medicine Stephania tetrandra S. Moore, enhanced the anti-lung cancer effect of mTOR inhibitor everolimus (EVE). The combination of EVE and FCL was effective to activate Notch 3, and subsequently evoked its downstream target c-MYC. The blockage of Notch 3 signal by the molecular inhibit...
Source: Biochemical Pharmacology - March 18, 2020 Category: Drugs & Pharmacology Authors: Li T, Xu XH, Guo X, Yuan T, Tang ZH, Jiang XM, Xu YL, Zhang LL, Chen X, Zhu H, Shi JJ, Lu JJ Tags: Biochem Pharmacol Source Type: research

Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC)
Publication date: May 2020Source: Biomedicine & Pharmacotherapy, Volume 125Author(s): Yinxue Song, Bin Zhou, Xiangyang Du, Yong Wang, Jie Zhang, Yanqiu Ai, Zongjiang Xia, Gaofeng Zhao
Source: Biomedicine and Pharmacotherapy - February 25, 2020 Category: Drugs & Pharmacology Source Type: research

Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC).
Abstract Non-small cell lung cancer (NSCLC) is a common diagnosed cancer disease worldwide and its management remains a challenge. Synergistic cancer therapeutic strategy is interesting for multiple advantages, such as excellent targeting accuracy, low side effects, and promoted therapeutic efficiency. In the present study, myricetin (Myr)-loaded mesoporous silica nanoparticles (MSN) combined with multidrug resistance protein (MRP-1) siRNA was prepared. The surface of the synthesized nanoparticles was modified with folic acid (FA) to promote the therapeutic efficiency of Myr for the treatment of NSCLC. The collect...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 21, 2020 Category: Drugs & Pharmacology Authors: Song Y, Zhou B, Du X, Wang Y, Zhang J, Ai Y, Xia Z, Zhao G Tags: Biomed Pharmacother Source Type: research

Chalcomoracin inhibits cell proliferation and increases sensitivity to radiotherapy in human non-small cell lung cancer cells via inducing endoplasmic reticulum stress-mediated paraptosis.
In this study, we investigated the effects of CMR against human non-small cell lung cancer cells and the underlying mechanisms. We found that CMR dose-dependently inhibited the proliferation of human lung cancer H460, A549 and PC-9 cells. Furthermore, exposure to low and median doses of CMR induced paraptosis but not apoptosis, which was presented as the formation of extensive cytoplasmic vacuolation with increased expression of endoplasmic reticulum stress markers, Bip and Chop, as well as activation of MAPK pathway in the lung cancer cells. Knockdown of Bip with siRNA not only reduced the cell-killing effect of CMR, but ...
Source: Acta Pharmacologica Sinica - February 16, 2020 Category: Drugs & Pharmacology Authors: Zhang SR, Zhang XC, Liang JF, Fang HM, Huang HX, Zhao YY, Chen XQ, Ma SL Tags: Acta Pharmacol Sin Source Type: research

Regulation of breast cancer resistance protein and P ‐glycoprotein by ezrin, radixin and moesin in lung, intestinal and renal cancer cell lines
ConclusionsOur findings indicate that regulation of BCRP and P ‐gp functions by ERM proteins is organ‐specific. Thus, if the appropriate ERM protein(s) are functionally suppressed, accumulation of BCRP or P‐gp substrates in lung, intestine or kidney cancer tissue might be specifically increased.
Source: Journal of Pharmacy and Pharmacology - February 13, 2020 Category: Drugs & Pharmacology Authors: Kentaro Yano, Chiaki Okabe, Kenta Fujii, Yuko Kato, Takuo Ogihara Tags: Research Paper Source Type: research

Effects of lncRNA SNHG20 on proliferation and apoptosis of non-small cell lung cancer cells through Wnt/ β-catenin signaling pathway.
CONCLUSIONS: LncRNA SNHG20 promotes the proliferation and inhibits the apoptosis of NSCLC cells by targeting miR-197 through the Wnt/β-catenin signaling pathway. PMID: 31957836 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - January 21, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Arenobufagin, isolated from toad venom, inhibited epithelial-to-mesenchymal transition and suppressed migration and invasion of lung cancer cells via targeting IKKβ/NFκB signal cascade
ConclusionIn the present study, we explored the molecular mechanism of Arg prohibiting the metastasis of lung cancer cells in vitro and in vivo, which displayed Arg could target IKKβ to inactive NFκB signaling cascade and further change the expression of proteins related to EMT. These results highlight the potential of toad venom as a potential chemotherapeutic agent and warrant its development as the clinical therapy for lung cancer.Graphical abstract
Source: Journal of Ethnopharmacology - December 21, 2019 Category: Drugs & Pharmacology Source Type: research

Hydrogen sulfide modulates epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via HIF-1 α activation.
Hydrogen sulfide modulates epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via HIF-1α activation. Biochem Pharmacol. 2019 Dec 20;:113775 Authors: Wang M, Yan J, Cao X, Hua P, Li Z Abstract Hydrogen sulfide (H2S) has been frequently implicated in tumor progression. However, the exact regulation mechanism of H2S in human non-small cell lung cancer (NSCLC) has not been fully elucidated. Here, analysis of NSCLC biopsies and adjacent non-tumor tissues revealed selectively high levels of endogenous H2S-producing enzymes, cystathionine-beta-synthase (CBS), cystathionine-gamm...
Source: Biochemical Pharmacology - December 19, 2019 Category: Drugs & Pharmacology Authors: Wang M, Yan J, Cao X, Hua P, Li Z Tags: Biochem Pharmacol Source Type: research

Engineered Extracellular Vesicles with Synthetic Lipids via Membrane Fusion to Establish Efficient Gene Delivery
Publication date: Available online 9 November 2019Source: International Journal of PharmaceuticsAuthor(s): Yong-Yu Jhan, Daniel Prasca-Chamorro, Guillermo Palou Zuniga, David Mitchell Moore, Shreedevi Arun Kumar, Akhilesh K. Gaharwar, Corey J. BishopAbstractThe low yield of extracellular vesicle (EV) secretion is a major obstacle for mass production and limits their potential for clinical applications as a drug delivery platform. Here, we mass produced engineered extracellular vesicles (eEVs) by fusing the surface composition of EVs with lipid-based materials via a membrane extrusion technique. A library of lipids (DOTAP, ...
Source: International Journal of Pharmaceutics - November 10, 2019 Category: Drugs & Pharmacology Source Type: research

Ouabain impairs cancer metabolism and activates AMPK-Src signaling pathway in human cancer cell lines.
In this study we showed that treatment with ouabain (25 nM) caused simultaneous activation of AMPK and Src signaling pathways in human lung cancer A549 cells and human breast cancer MCF7 cells. Cotreatment with AMPK inhibitor compound C or siRNA greatly abrogates ouabain-induced Src activation, whereas cotreatment with Src inhibitor PP2 has little effect on ouabain-induced AMPK activity, suggesting that AMPK served as an upstream regulator of the Src signaling pathway. On the other hand, ouabain treatment greatly depletes ATP production in A549 and MCF7 cells, and supplement of ATP (100 μM) blocked ouabain-induced AMP...
Source: Acta Pharmacologica Sinica - September 11, 2019 Category: Drugs & Pharmacology Authors: Shen JJ, Zhan YC, Li HY, Wang Z Tags: Acta Pharmacol Sin Source Type: research

PLCE1 inhibits apoptosis of non-small cell lung cancer via promoting PTEN methylation.
CONCLUSIONS: PLCE1 inhibits cell apoptosis of NSCLC by promoting PTEN methylation. PMID: 31364122 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - August 2, 2019 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles
ConclusionsBSA nanoparticles loaded with mutant specific siRNA are a promising therapeutic approach for KRAS-mutant cancers.
Source: Pharmaceutical Research - July 8, 2019 Category: Drugs & Pharmacology Source Type: research

JMJD3 enhances invasiveness and migratory capacity of non-small cell lung cancer cell via activating EMT signaling pathway.
CONCLUSIONS: JMJD3 expression was found conspicuously increased in NSCLC, which might be close relevant to NSCLC lymphatic or distant metastasis as well as patients' poor prognosis. Therefore, we speculated that JMJD3 could promote invasiveness and migratory capacity of non-small cell lung cancer cells by activating EMT process. PMID: 31210309 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - June 20, 2019 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research